1.46

3.95% -0.06

After Hours: 1.48 0.02 +1.37%

Traws Pharma Inc (TRAW)

Overview News Price History Discussions Forecast

Traws Pharma Inc stock is traded at $1.46, with a volume of 376.27K. It is down -3.95% in the last 24 hours and up +12.31% over the past month. Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.

Previous Close:

$1.52

Open:

$1.5

24h Volume:

376.27K

Relative Volume:

0.18

Market Cap:

$22.12M

Revenue:

$2.79M

Net Income/Loss:

$9.17M

P/E Ratio:

1.0665

EPS:

1.369

Net Cash Flow:

$-20.77M

1W Performance:

-2.01%

1M Performance:

+12.31%

6M Performance:

-45.93%

1Y Performance:

+5.04%

1-Day Range:

$1.45

$1.54

1-Week Range:

$1.45

$1.7199

52-Week Range:

$0.995

$3.265

Traws Pharma Inc Stock (TRAW) Company Profile

Name

Traws Pharma Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

267-759-3680

Address

12 PENNS TRAIL, NEWTOWN

Employee

Twitter

Next Earnings Date

2026-05-21

Latest SEC Filings

TRAW's Discussions on Twitter

Compare TRAW vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRAW Traws Pharma Inc	1.46	23.03M	2.79M	9.17M	-20.77M	1.369
VRTX Vertex Pharmaceuticals Inc	447.54	113.70B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.78	65.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	835.99	52.14B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.98	40.73B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.48	32.87B	742.00K	-1.37B	-1.07B	-7.0731

Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-25	Initiated	H.C. Wainwright	Buy
Mar-01-22	Initiated	Ladenburg Thalmann	Buy
May-18-21	Initiated	Guggenheim	Buy
Mar-01-18	Reiterated	H.C. Wainwright	Buy
Jan-17-18	Downgrade	Maxim Group	Buy → Hold
Oct-09-17	Initiated	H.C. Wainwright	Buy
Apr-27-17	Initiated	Laidlaw	Buy
Jul-01-15	Upgrade	Piper Jaffray	Neutral → Overweight
May-05-15	Initiated	H.C. Wainwright	Buy

View All

Traws Pharma Inc Stock (TRAW) Latest News

06:35 AM

TRAW | Traws Pharma, Inc. Common Executive Compensation - Quiver Quantitative

06:35 AM

May 29, 2026

Traws Pharma (NASDAQ: TRAW) 2026 proxy seeks share plan and warrant approvals - Stock Titan

May 29, 2026

May 28, 2026

Traws Pharma announces new antiviral program - BioWorld News

May 28, 2026

Newtown-based Traws Pharma advances experimental antiviral therapy - Pennsylvania Business Report -

May 28, 2026

May 27, 2026

TRAW Advances Novel Anti-Viral Agent for Hantavirus and Ebola - GuruFocus

May 27, 2026

Traws Pharma Advances Novel Broad-Spectrum Antiviral Agent Targeting Hantavirus, Ebola, and Lassa with Innovative Dual-Strike Mechanism - Quiver Quantitative

May 27, 2026

Traws Pharma (NASDAQ: TRAW) advances broad antiviral for Hantavirus, Ebola - Stock Titan

May 27, 2026

New dual-strike pill aims to tackle deadly Ebola and hantavirus outbreaks - Stock Titan

May 27, 2026

Traws Pharma, Inc. Files Form 8-K with SEC – Company Details, Address, and Legal Opinion Included - Minichart

May 27, 2026

May 26, 2026

TRAW - Finviz

May 26, 2026

Traws Pharma launches $3.13M ATM sales under $50M shelf with Citizens JMP - TradingView

May 26, 2026

Traws Pharma (NASDAQ: TRAW) outlines $3,128,399 baby shelf ATM capacity - Stock Titan

May 26, 2026

Traws Pharma (TRAW) Stock Forecast & Analyst Ratings - Moomoo

May 26, 2026

May 23, 2026